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Objectives. We sought to investigate whether, in humans, the
timing and incidence of a relapse of atrial fibrillation (AF) during
the first month after cardioversion indicates the presence of
electrical remodeling and whether this could be influenced by
prevention of intracellular calcium overload during AF.
Background. Animal experiments have shown that AF induces
shortening of the atrial refractory period, resulting in an in-
creased vulnerability for reinduction of AF. This electrical remod-
eling was completely reversible within 1 week after cardioversion
of AF and was presumably related to intracellular calcium over-
load.
Methods. Using transtelephonic monitoring in 61 patients
cardioverted for chronic AF, we evaluated the daily incidence of
recurrence of AF and determined, by Cox regression analysis, the
influence of patient characteristics and medication on relapse of
AF.
Results. During 1 month of follow-up, 35 patients (57%) had a
relapse of AF, with a peak incidence during the first 5 days after
cardioversion. Furthermore, in patients with a recurrence of AF,
there was a positive correlation between the duration of the
shortest coupling interval of the premature atrial beats after
cardioversion and the timing of the recurrence of AF (p 5 0.0013).
Multivariate analysis revealed that the use of intracellular
calcium-lowering drugs during AF was the only significant vari-
able related to maintenance of sinus rhythm after cardioversion
(p 5 0.03).
Conclusions. The daily distribution of recurrences of AF sug-
gests a temporary vulnerable electrophysiologic state of the atria.
Use of intracellular calcium-lowering medications during AF
appeared to reduce recurrences, possibly due to a reduction of
electrical remodeling during AF.
(J Am Coll Cardiol 1998;31:167–73)
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In patients with atrial fibrillation (AF), long-term maintenance
of sinus rhythm after successful cardioversion is difficult,
mainly because of a high recurrence rate of AF within the first
month after cardioversion (1–9). The exact time course of the
AF recurrences is largely unknown. Experimental studies in
chronically instrumented goats have shown that AF induces
changes in the electrophysiologic properties of the atria, which
could explain the progressive vulnerability of the atria for AF
(10). Prolonged maintenance of AF by a fibrillation pacemaker
led to long-term shortening of the atrial refractory period, in
the absence of significant effects on intraatrial conduction
velocity (10,11). This electrical remodeling of the atria, which
in the goat is completely reversible within 1 week after
restoration of sinus rhythm (10), may account for an increased
vulnerability for recurrences of AF early after cardioversion.
The underlying mechanisms behind AF-induced electrical
remodeling are still incompletely understood. However, there
are some indications that intracellular calcium overload plays
an important role. Verapamil administered during rapid atrial
pacing (12,13) or short episodes of artificially induced AF (14)
significantly reduced the electrical remodeling of the atria. In
contrast, administration of calcium gluconate, resulting in
relative hypercalcemia during rapid atrial pacing in dogs,
induced a distinct delay in recovery from electrical remodeling
after cessation of pacing (12).
If in humans the time course of reversal of AF-induced
electrical remodeling is the same as that in goats, one would
expect the incidence of relapses of AF to be highest during the
first week after cardioversion. Furthermore, if electrical re-
modeling in humans is related to intracellular calcium over-
load, the frequency of relapse might be lowered by drugs that
lower the intracellular calcium concentration, such as calcium
channel blockers and beta-adrenergic receptor blockers. The
aim of the present study was to investigate whether, in humans,
the timing and incidence of a relapse of AF during the first
month after cardioversion indicates the presence of electrical
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remodeling and whether this could be influenced by prevention
of intracellular calcium overload during AF.
Methods
Patients. Sixty-one consecutive patients, who were admit-
ted to the hospital between March 1995 and October 1995 to
undergo electrical cardioversion of chronic AF, were asked to
have their heart rhythm checked on a daily basis during a
1-month period after successful electrical cardioversion. Be-
fore cardioversion, heart rate was controlled by drugs to lower
the rest heart rate to ,100 beats/min. The specific medication
depended on the physician’s preference as well as on concom-
itant heart disease (e.g., hypertension and ischemic heart
disease). The drugs included digitalis, verapamil, diltiazem or
beta-blockers. In case the rest heart rate did not decrease ,100
beats/minute, a combination of the aforementioned drugs was
prescribed.
Electrical cardioversion was performed under general an-
esthesia with 20 mg of intravenous etomidate. Only in case of
a recardioversion, patients received antiarrhythmic drugs ac-
cording to our previously published serial drug testing strategy
(15). Unless contraindicated, patients continued to receive
rate-control medication after cardioversion to prevent a high
heart rate in the event of recurrence of AF.
Immediately after electrical cardioversion, a 12-lead con-
tinuous electrocardiogram (ECG) was recorded during 2 min.
Number and coupling intervals of the premature atrial beats
(PABs) were measured. Thereafter, cardiac rhythm was mon-
itored by telemetry for at least 4 h. Before hospital discharge,
the patients were instructed in using a transtelephonic moni-
toring device (Cardio-beeper II, Survival Technology Inc.).
They were requested to make a 60-s recording every morning
immediately after they woke up and to contact the hospital
daily between 9:00 and 10:00 AM. In the transtelephonic
monitoring laboratory, the digitized ECG recording was de-
coded and the rhythm was evaluated.
Definition of terms. Chronic atrial fibrillation was defined
as AF documented repeatedly on a 12-lead ECG without
intercurrent sinus rhythm at consecutive outpatient visits be-
fore study inclusion. To exclude patients with paroxysmal
(stress-induced) adrenergic AF during these visits, 24-h Holter
monitoring was also performed. Underlying heart disease was
determined from the patient’s history, physical examination,
chest X-ray film, echocardiogram and, if available, coronary
angiogram. Total arrhythmia duration was defined as the dura-
tion of the arrhythmia starting from the first episode of
documented AF.
The group of calcium channel blockers consisted of vera-
pamil, diltiazem and dihydropyridines. Beta-blockers included
sotalol, which is also classified as an antiarrhythmic drug. The
group of intracellular calcium-lowering drugs consisted of
calcium channel blockers and beta-blockers. Sotalol was ex-
cluded from the group of intracellular calcium-lowering drugs
despite its calcium-lowering beta-blocker activity, because it
theoretically also could increase intracellular calcium load by
virtue of its ability to prolong the plateau phase of the action
potential.
Statistical analysis. The main variable of the study was the
time between successful cardioversion and eventual recurrence
of AF within 1 month. Data are presented as the mean value 6
SD. Median values were used in case a variable was nonuni-
formly distributed. For comparison of groups, continuous and
normally distributed variables were tested using the one-way
analysis of variance. Variables with a nonuniform distribution
were tested using the Wilcoxon two-sample test. Frequencies
were compared using the Fisher exact test for equality of
proportions. To find variables possibly related to recurrence of
AF, univariate Cox regression analysis was performed on all
variables related to AF. Subsequently, variables with a p value
,0.20 were selected for multiple Cox regression analysis.
Linearity of the continuous variables in relation to the occur-
rence and timing of relapses of AF was assessed by evaluating
the coefficients of the quartiles of their distribution. In case of
a linear trend of the estimated coefficients of the different
groups, the variable was introduced as continuous. If no
linearity was apparent, the variable was categorized by group-
ing the quartiles with similar coefficients. The Spearman
rank-sum test was used to study the correlation between the
shortest coupling interval of the premature atrial complexes
immediately after cardioversion and the timing of recurrence
of AF. A p value ,0.05 was considered statistically significant.
Analyses were performed using SAS statistical software (SAS,
version 6.11).
Results
Patient characteristics and relapses of AF. Patient charac-
teristics and medications of the group of 61 patients are given
in Table 1. During follow-up, 35 patients (57%) had a relapse
of AF. Figure 1 shows the daily distribution of recurrences of
AF. Of the total of 35 relapses of AF during the first month
after cardioversion, 22 (63%) occurred during the first 5 days.
Thereafter, the daily recurrence of AF substantially decreased.
Table 2 compares the patients with and without a relapse of
AF during the first month after cardioversion. In the group
that remained in sinus rhythm, significantly more patients were
taking intracellular calcium-lowering drugs before cardiover-
sion (p 5 0.04). The proportion of patients taking calcium
antagonists or beta-blockers before cardioversion was border-
line significant (p 5 0.06 and p 5 0.08, respectively). In
contrast, monotherapy with digoxin before cardioversion (i.e.,
without concomitant intracellular calcium-lowering medica-
Abbreviations and Acronyms
AF 5 atrial fibrillation
ECG 5 electrocardiogram, electrocardiographic
PAB 5 premature atrial beat
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tions) seemed to be more prevalent in patients who had a
relapse of AF within 1 month after cardioversion (p 5 0.06).
Multivariate analysis revealed that the use of intracellular
calcium-lowering drugs before cardioversion (i.e., during AF)
was the only independent predictor for maintenance of sinus
rhythm after successful cardioversion (p 5 0.03). Figure 2
shows the arrhythmia-free survival curves of the patients who
used intracellular calcium-lowering drugs during AF and those
who did not. The first group experienced significantly fewer
relapses of AF, especially during the first 2 weeks after
cardioversion, compared with the group of patients who did
not use intracellular calcium-lowering drugs during AF. There
were no significant differences in other patient characteristics
between the patients with and those without intracellular
calcium-lowering drugs; in particular, left ventricular function
in both groups was comparable (Table 3).
Premature atrial beats and relapse of AF. Immediately
after cardioversion, 37 patients (61%) had PABs. Of this
group, 23 patients (62%) had a recurrence of AF. The
presence or number of PABs had no influence on the timing of
an eventual relapse of AF. However, in the group of patients
who had a relapse of AF, there was a significant correlation
between the shortest coupling interval of PABs recorded after
cardioversion and the time of relapse (Fig. 3). Patients having
PABs with short coupling intervals were prone to have an early
relapse, whereas patients with late PABs tended to have a
relapse of AF later during follow-up.
The use of beta-blockers, calcium channel blockers or
antiarrhythmic drugs did not influence the number or coupling
intervals of the PABs recorded immediately after cardiover-
sion or during follow-up.
Discussion
To our knowledge, this is the first study to document the
moment of recurrence of AF after successful electrical cardio-
version with a time resolution of 1 day. Our principal finding is
that there is a relatively high incidence of recurrences of AF
during the first 5 days after cardioversion. Moreover, drugs
that are known to lower the intracellular calcium concentra-
tion, when administered during AF, lowered the recurrence
rate of AF. These findings are in agreement with previously
reported animal studies investigating electrical remodeling of
the atria (10,12,13) and are the first clinical illustration of these
experimental findings.
Figure 1. The daily incidence of relapse of AF during 1 month of
follow-up. There was an increased incidence of relapse of AF during
the first 5 days immediately after cardioversion compared with the rest
of the follow-up period. Pts 5 patients.
Table 1. Patient Characteristics
Age (yr) 61 6 12
Male/female (n) 34/27
Underlying heart disease (%)*
Coronary artery disease 16
Valvular disease 23
Systemic hypertension 32
Congenital heart disease 13
Dilated cardiomyopathy 5
“Lone” arrhythmia 21
Arrhythmia history
Median duration in months (range) 7 (1–158)
No. of previous ECVs 0.6 6 0.9
Medications during AF (%)*
Digitalis monotherapy 38
Calcium channel blockers 36
Beta-blockers 26
Intracellular calcium-lowering drugs 46
Antiarrhythmic drugs 16
Sotalol 7
Propafenone 3
Amiodarone 6
Medications after cardioversion (%)*
Digitalis monotherapy 30
Calcium channel blockers 41
Beta-blockers 34
Intracellular calcium-lowering drugs 49
Antiarrhythmic drugs 33
Sotalol 16
Propafenone 3
Flecainide 5
Amiodarone 8
NYHA functional class (%)
I 51
II 38
III 11
Echocardiographic variables
Left atrial size, long-axis view (mm) 45 6 7
Left atrial size, apical view (mm) 64 6 9
Right atrial size (mm) 59 6 7
LVESD (mm) 51 6 6
LVEDD (mm) 38 6 7
Fractional shortening (%) 27 6 8
*More than one per patient possible. Data are presented as mean value 6
SD, unless otherwise indicated. AF 5 atrial fibrillation; ECVs 5 electrical
cardioversions; LVEDD 5 left ventricular end-diastolic diameter; LVESD 5 left
ventricular end-systolic diameter; NYHA 5 New York Heart Association.
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Electrical remodeling of the atria. Elaborate mapping
studies (16–23) have confirmed the hypothesis originally put
forward by Moe et al. (24–26) that AF is based on multiple
reentrant wavelets wandering through the atrial myocardium.
The wavelength of these wavelets, defined as the distance
traveled during the duration of the refractory period of the
atrial cells (wavelength 5 conduction velocity 3 refractory
period) (27,28), is a determinant for the induction of these
reentrant arrhythmias. The smaller the wavelength of the
circulating wavelets, the easier AF was induced (19,20,29,30).
Previous invasive clinical studies have reported short atrial
refractory periods (31,32) and loss of the physiologic rate-
dependent adaptation of the refractory period (33–36) in
patients after they have had electrical cardioversion of chronic
AF. In the two studies by Olsson et al. (31) and Cotoi et al.
(32), a short duration of the right atrial monophasic action
potential correlated with a higher tendency of the arrhythmia
to recur. Recent animal experiments have shown that artifi-
cially maintained AF (10–12) or rapid atrial pacing (13)
induces a long-term shortening of the atrial refractory period,
without significant changes in intraatrial conduction velocity.
Daoud et al. (37) showed that also in patients undergoing a
routine electrophysiologic investigation, shorter episodes of
Figure 2. Cox survival analysis comparing the maintenance of sinus
rhythm between patients pretreated with intracellular calcium-
lowering drugs during AF and patients not pretreated with these drugs.
The patients without intracellular calcium-lowering drugs were more
vulnerable for relapse of AF over a longer period of time.
Table 2. Univariate Comparison of Characteristics in Patients With
and Without Recurrence of Atrial Fibrillation
Relapse
(n 5 35)
(57%)
Sinus rhythm
(n 5 26)
(43%)
p
Value
Age (yr) 63 6 11 59 6 13 0.19
Male/female 23/12 11/15 0.12
Underlying heart disease (%)*
Coronary artery disease 14 19 0.73
Valvular disease 17 31 0.24
Systemic hypertension 31 31 1.0
Congenital heart disease 20 23 0.85
Dilated cardiomyopathy 6 4 1.0
“Lone” arrhythmia 23 20 0.85
Arrhythmia history
Median duration in months (range) 7 (1–158) 6 (1–108) 0.86
Number of previous ECVs 0.5 6 1.0 0.5 6 0.8 0.89
Medications during AF (%)*
Digitalis monotherapy 49 23 0.06
Calcium channel blockers 26 50 0.06
Beta-blockers 17 38 0.08
Intracellular calcium-lowering drugs 34 62 0.04
Antiarrhythmic drugs 14 19 0.46
Sotalol 3 12 0.30
Propafenone 6 0 0.50
Amiodarone 6 8 1.0
Medications after cardioversion (%)*
Digitalis monotherapy 34 23 0.40
Calcium channel blockers 31 54 0.12
Beta-blockers 26 46 0.11
Intracellular calcium-lowering drugs 40 62 0.12
Antiarrhythmic drugs 31 34 0.28
Sotalol 11 23 0.30
Flecainide 9 0 0.25
Propafenone 6 0 0.50
Amiodarone 6 12 0.64
NYHA functional class (%)
I 60 38 0.25
II 31 46
III 9 15
Echocardiographic variables
Left atrial size, long-axis view (mm) 44 6 5 47 6 8 0.14
Left atrial size, apical view (mm) 63 6 10 66 6 7 0.19
Right atrial size (mm) 58 6 7 59 6 7 0.70
LVEDD (mm) 50 6 7 52 6 6 0.53
LVESD (mm) 37 6 8 38 6 7 0.78
Fractional shortening (%) 27 6 8 27 6 8 0.98
*More than one per patient possible. Data are presented as mean value 6
SD, unless otherwise indicated. Abbreviations as in Table 1.
Table 3. Univariate Comparison of Indexes of Left Ventricular
Function in Patients With and Without Calcium-Lowering
Medications During Atrial Fibrillation
No Ca-low
(n 5 33)
(54%)
Ca-low
(n 5 28)
(46%)
p
Value
NYHA functional class (%)
I 52 50 1.0
II 36 39
III 12 11
Echocardiographic variables
Left atrial size, long-axis view (mm) 47 6 5 44 6 7 0.09
Left atrial size, apical view (mm) 66 6 9 64 6 9 0.26
Right atrial size (mm) 59 6 7 58 6 7 0.69
LVEDD (mm) 50 6 7 51 6 5 0.65
LVESD (mm) 38 6 9 37 6 6 0.70
Fractional shortening (%) 25 6 8 29 6 8 0.22
Data are presented as percent of patients or mean value 6 SD. Ca-low 5
calcium-lowering drugs; other abbreviations as in Table 1.
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artificially induced AF shortened the refractory period signif-
icantly. This electrical remodeling of the atria results in a
shorter wavelength of the atrial impulses (10) and may explain
the increased vulnerability for recurrence of AF after cardio-
version.
Recovery from electrical remodeling. In goats with pacing-
induced chronic AF, electrical remodeling of the atria was
completely reversible within 1 week after restoration of sinus
rhythm (10). Such recovery from electrical remodeling of the
atria has not yet been studied in patients with chronic AF.
However, the present observation that the recurrences of AF
clearly diminished after the first 5 days after cardioversion may
be the clinical representation of recovery from electrical
remodeling of the atria in patients who have been cardioverted
for chronic AF.
In studies examining the recovery of contractile function of
the atria after chronic AF, it took ;1 week to 1 month for the
atria to regain their normal mechanical function, depending on
the duration of the arrhythmia (38,39). In case both postcar-
dioversion contractile dysfunction and electrical remodeling of
the atria represent the same AF-induced pathologic process,
these studies (38,39) lend further support to the concept of
postcardioversion reversal of electrical remodeling in patients
cardioverted for chronic AF.
Role of intracellular calcium-lowering drugs. The only
significant predictor for maintenance of sinus rhythm during
follow-up was the use of intracellular calcium-lowering drugs
administered during AF. Recent animal studies have suggested
that intracellular calcium is very important in the process of
electrical remodeling of the atria (12,13). In goats, pacing-
induced electrical remodeling was significantly reduced by the
administration of verapamil during the arrhythmia. As a result,
after cessation of rapid atrial pacing the atrial refractory period
returned sooner to its control value (13). In contrast, rapid
atrial pacing during hypercalcemia in dogs resulted in a distinct
delay of recovery from electrical remodeling (12). Our present
observations are in agreement with these animal studies.
Figure 2 suggests that the overall reduction in relapse of AF in
patients using calcium-lowering drugs was mainly due to a
reduction during the first 2 weeks after cardioversion. One
could speculate that the intracellular calcium-lowering drugs
administered during AF reduce electrical remodeling, which in
turn would lead to a more rapid recovery from electrical
remodeling after cardioversion. This would explain the ob-
served lower incidence of relapse of AF in this study.
Previously reported studies examining the effect of calcium
channel blockers (40–45) or beta-blockers (46) on mainte-
nance of sinus rhythm after cardioversion of chronic AF
showed less clear results. However, in these studies the med-
ication was initiated after successful cardioversion (i.e., after
AF-induced electrical remodeling was complete). In the
present study we also demonstrated no beneficial effects of
these drugs administered after cardioversion.
Antiarrhythmic drugs after cardioversion. After cardio-
version of chronic AF, antiarrhythmic medication was initiated
in 20 patients (33%). However, this did not prevent early
recurrences. This is in agreement with the decreased efficacy of
antiarrhythmic drugs in converting AF of longer duration
(47–50). These observations suggest that antiarrhythmic drugs
might be less effective in the setting of electrical remodeling of
the atria. The protective effect of intracellular calcium-
lowering drugs on recurrences of AF, as described in this study,
is in line with the findings of a recent study in which concom-
itant administration of verapamil during oral amiodarone
therapy during 1 month was an independent predictor of
pharmacologic cardioversion of AF (51). Reduction of electri-
cal remodeling by decreasing intracellular calcium overload
could be the common mode of action in both studies.
Premature atrial complexes and recurrence of AF. The
number and timing of PABs, recorded immediately after
cardioversion, did not predict recurrence of AF during follow-
up. However, in the patients who had a relapse of AF, the
shortest coupling interval of the PABs recorded immediately
after cardioversion was significantly correlated with the timing
of the relapse, in the sense that a short coupling interval
predicted an early relapse, whereas patients with longer cou-
pling intervals had their recurrence later during follow-up. The
explanation for this finding may relate to the fact that for a
premature stimulus to induce AF, heterogeneity of refractori-
ness is necessary. Immediately after cardioversion, electrical
remodeling may have shortened the refractory period of the
atria to such an extent that longer PABs do not encounter
dispersion of refractoriness. Only later after cardioversion,
when the refractory period has lengthened again, due to
reversibility of electrical remodeling, is the timing of these
longer PABs, which were not initially arrhythmogenic, now
close to the refractory period and may fall well within the
“window of dispersion of refractoriness,” resulting in a relapse
of AF. The positive correlation between the coupling interval
of the PAB immediately after cardioversion and the timing of
Figure 3. Relation between the shortest coupling interval of the
premature atrial complex (PAC) recorded immediately after electrical
cardioversion (ECV) and the timing of relapse of AF in those patients
in whom sinus rhythm (SR) could not be maintained during follow-up.
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relapse of AF might indicate a gradual lengthening of the
average refractory period during follow-up. This observation
supports the hypothesis of recovery from electrical remodeling
after restoration of sinus rhythm.
Study limitations. This is an observational study on the
maintenance of sinus rhythm after cardioversion of chronic AF
in only 61 consecutive patients, during a rather short follow-up
period. Administration of intracellular calcium-lowering drugs
was not randomized. Despite the fact that the characteristics of
the patients using calcium-lowering drugs were not signifi-
cantly different from those of the patients not using these
drugs, our results may be influenced by a selection bias.
Randomized studies examining the effects of intracellular
calcium-lowering medications administered during arrhythmia
are needed to confirm the results of the present study. Al-
though a reduction of intracellular calcium overload has been
proposed to be the mechanism by which calcium antagonists
reduce electrical remodeling in the animal experiments, intra-
cellular calcium concentrations have not been measured.
Therefore, it is not known whether calcium antagonists and
beta-blockers may be grouped together, both being intracellu-
lar calcium-lowering drugs, although they acted in the same
way during univariate analysis.
Clinical implications. In studies examining the long-term
efficacy of electrical cardioversion, the recurrences of AF
during the first month after cardioversion consist of .50% of
the total recurrences during 1 year of follow-up (1–9). In case
prospective, placebo-controlled, invasive electrophysiologic
studies confirm the observations and the proposed mechanism,
as described in the present study, medical endeavor should
focus on reduction of electrical remodeling during AF to
improve long-term maintenance of sinus rhythm. The finding
that intracellular calcium-lowering drugs administered during
arrhythmia are associated with an improved arrhythmia prog-
nosis may lead to future directions of research.
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